AACR Meeting Abstracts
HOME HELP FEEDBACK HOW TO CITE ABSTRACTS ARCHIVE CME INFORMATION SEARCH
Cancer ResearchClinical Cancer Research
Cancer Epidemiology Biomarkers & PreventionMolecular Cancer Therapeutics
Molecular Cancer ResearchCancer Prevention Research
Cancer Prevention Journals PortalCancer Reviews Online
Annual Meeting Education BookMeeting Abstracts Online
 QUICK SEARCH:   [advanced]




This Article
Services
Right arrow Similar articles in this journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnes-Nkrumah, Y. M.
Right arrow Articles by Thomas, R. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Barnes-Nkrumah, Y. M.
Right arrow Articles by Thomas, R. D.
[Proc Amer Assoc Cancer Res, Volume 47, 2006]


Carcinogenesis 5: Environmental and Endogenous Carcinogens

Abstract #1909

Diallyl sulfide inhibits 2,2’4,4’-tetra brominated biphenyl ether (BDE-47) induced DNA strand breaks and cell proliferation in MCF10A breast epithelial cells

Yasmeen M. Barnes-Nkrumah, Selina F. Darling-Reed, Ayoola A. Aboyade-Cole, Alicia Tucker and Ronald D. Thomas

Florida A&M University, Tallahassee, FL

Polybrominated diphenyl ethers (PBDEs) are a group of 209 congeners that are used in a variety of products as flame retardants, and have been found in the breast tissue and breast milk of women sampled in North America, Europe and Asia. 2,2’,4,4’-tetra brominated diphenyl ether (BDE-47) is the most abundant PBDE congener found in human, animal, and environmental samples, however the role of BDE-47 in breast cancer development is not known. Diallyl sulfide (DAS), an organosulfur compound found in garlic is a recognized chemo-preventive agent and has been shown to decrease DNA strand breaks induced by carcinogens. We hypothesize that BDE-47 will cause cell proliferation and induce DNA strand breaks in MCF10A cells, which will be inhibited by diallyl sulfide. To test this hypothesis MCF10A cells were pre-treated for 6 hours with various concentrations of DAS (1, 10, 100 µM) and treated for 24 hours with BDE-47 (1, 10, 100µM). DNA strand breaks were determined by Comet Assay analysis. To determine cell proliferation MCF10A cells were treated with BDE-47 (0.1 µM) for 24, 48, and 72 hours following a six hour pretreatment with 1.0 µM DAS. The MTS assay was used to determine cell viability. Cells treated with BDE-47 (1,10, & 100 µM) increased DNA strand breaks as indicated by an increase in the mean olive tail moment (8.885, 21.025, & 22.670) with increasing concentration. DAS at a concentration of 1 µM completely inhibited BDE-47 induced DNA strand breaks when compared to the control. BDE-47 (0.1 µM) decreased cell viability to 77% at 24 hours, and cell viability increased at 48 and 72 hours to 105% and 127% of the control. The addition of DAS (1 µM) increased the BDE-47 induced reduction in cell viability from 77% to 104% at 24 hours. However, DAS reduced BDE-47 induction in cell proliferation at 48 and 72 hours. We have demonstrated that BDE-47 causes DNA strand breaks and DAS inhibits these strand breaks. We have also demonstrated that BDE-47 decreases cell viability at 24 hours and stimulated cell proliferation at 48 and 72 hours. We conclude that BDE-47 causes initial genotoxicity that leads to cell proliferation. DAS inhibits this damage and also stimulates cell death in cells that are possibly damaged by BDE-47 in such a way as to prevent cancer formation. Further studies are under way to elucidate the mechanism by which BDE-47 may be involved in breast cancer formation. This research is sponsored by a generous grant from NIH/RCMI Number G12 RR03020







HOME HELP FEEDBACK HOW TO CITE ABSTRACTS ARCHIVE CME INFORMATION SEARCH
Cancer ResearchClinical Cancer Research
Cancer Epidemiology Biomarkers & PreventionMolecular Cancer Therapeutics
Molecular Cancer ResearchCancer Prevention Research
Cancer Prevention Journals PortalCancer Reviews Online
Annual Meeting Education BookMeeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.